Lineage Cell Therapeutics Inc (LCTX)

[sokol]

Earn money? BTX will:

Renevia(®) successfully met the primary endpoint in a European pivotal study
for the treatment of HIV-Associated Facial Lipoatrophy. Treated patients
retained approximately 100% of transplanted volume at 6 months and there were
no device related serious adverse events noted during the trial.

BioTime plans to submit the Renevia(®) application for CE Marking later this
quarter with an expected approval in the second half of 2018. As the company
has previously reported, BioTime views the European trial as a gateway into a
larger multibillion-dollar market opportunity, like cosmetic facial
aesthetics. Currently, the U.S. facial fat transfer and dermal facial filler
market is estimated to be over 4 billion dollars and growing at or near
double digits.